Prostate Cancer Trial Results
- Observation as Good as Surgery for Some Men with Prostate Cancer
(Posted: 09/07/2012) - Many men diagnosed with early-stage prostate cancer could forego radical prostatectomy and live as long as men who have immediate surgery, according to long-awaited results from a clinical trial published July 19, 2012, in the New England Journal of Medicine (NEJM).
- Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening
(Posted: 02/17/2012) - Thirteen year follow-up data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial show higher incidence but similar mortality among men screened annually with the prostate-specific antigen (PSA) test and digital rectal examination (DRE).
- NIH-funded study shows increased prostate cancer risk from vitamin E supplements
(Posted: 10/11/2011) - Men who took 400 international units of vitamin E daily had more prostate cancers compared to men who took a placebo, according to an updated review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). The findings showed that, per 1,000 men, there were 76 prostate cancers in men who took only vitamin E supplements, vs. 65 in men on placebo over a seven-year period, or 11 more cases of prostate cancer per 1,000 men. This represents a 17 percent increase in prostate cancers relative to those who took a placebo. This difference was statistically significant and therefore is not likely due to chance.
- NIH-funded study shows reduction in death for men with intermediate-grade prostate cancer:
(Posted: 07/13/2011) - Short-term hormone therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared to treatment with radiation therapy alone, according to a clinical trial supported by NCI. Benefits of the combined treatment were limited mainly to patients with intermediate-risk disease and were not seen for men with low-risk prostate cancer, researchers say.
- Denosumab Reduces Risk of Bone Side Effects in Advanced Prostate Cancer
(Posted: 04/13/2011) - The biological agent denosumab (Xgeva) is more effective than zoledronic acid at decreasing the risk of bone fractures and other skeletal-related events (SRE) in men with castration-resistant metastatic prostate cancer, according to results from a randomized clinical trial reported online February 25, 2011, in The Lancet.